Figure 11.

Changes in ABCB1, ABCG2, or ABCC1 mRNA levels in physiological Caco-2 and LS174T cells (B,C) and non-small cell lung cancer (NSCLC) cellular models (D,E) after treatment with ensartinib. The tested drug concentration was chosen based on the results of MTT viability experiments (A) and previously determined Cmax values. During the gene induction assays, the cells were incubated with 0.5 µM ensartinib or 25 µM rifampicin for 24 and 48 h, and the mRNA levels of target genes were evaluated by qRT-PCR. ABCG2 was not detectable in LS174T and NCI-H1299 cells. The boundaries of downregulation/upregulation positivity based on the EMA’s recommendations are indicated by dotted lines. The plotted data are means ± SD from at least three independent experiments.